2025
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
Cummings J, Atri A, Feldman H, Hansson O, Sano M, Knop F, Johannsen P, León T, Scheltens P. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease. Alzheimer's Research & Therapy 2025, 17: 14. PMID: 39780249, PMCID: PMC11708093, DOI: 10.1186/s13195-024-01666-7.Peer-Reviewed Original ResearchConceptsSymptomatic ADAlzheimer's diseaseDouble-blindGlucagon-like peptide-1 receptor agonist semaglutidePlacebo-controlled phase 3 trialOnce-daily oral semaglutideClinical Dementia RatingMild cognitive impairmentAD-related processesAD biomarkersSafety of semaglutideDose-escalation regimenPhase 3 studyBaseline to weekEffect of semaglutidePhase 3 trialCognitive impairmentPathophysiology of Alzheimer's diseasePotential disease-modifying effectsDementia RatingSymptomatic Alzheimer's diseaseTreatment of type 2 diabetesPlacebo-ControlledType 2 diabetesDisease-modifying potential
2021
Reduced brain atrophy by gamma sensory stimulation in Alzheimer’s disease patients
Hajos M, Megerian J, Hempel E, Vaughan B, Malchano Z. Reduced brain atrophy by gamma sensory stimulation in Alzheimer’s disease patients. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.057849.Peer-Reviewed Original ResearchWhole brain volume lossBrain volumetric changesBrain volume lossBrain atrophyDisease patientsAlzheimer's disease patientsSensory stimulationAD patientsLateral ventriclePotential disease-modifying effectsAge-matched healthy subjectsDisease-modifying effectsAccelerated brain atrophyTemporal lobe volumeMild AD patientsMild-moderate ADMR imaging analysisMethods PatientsClinical presentationSame therapySham groupPatient populationVolume lossHippocampal volumeHealthy subjects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply